Stem cell transplant using modified donor cells for children and young adults

Allogeneic Hematopoietic Stem Cell Transplantation From an HLA-partially Matched Related or Unrelated Donor After TCR αβ+T Cells/CD19+ B Cell Depletion in Children and Young Adults Affected by Malignant or Non-Malignant Hematological Disorders

This study is testing a new way to use modified stem cells from partially matched donors to see if it can make transplants safer and more effective for children and young adults with blood diseases.

Quick facts

• Phase: Not applicable
• Study type: Interventional
• Enrollment: 204 (estimated)
• Ages: 1 Month to 60 Years
• Sex: All
• Sponsor: Stanford University (Academic / other)
• Locations: 1 site (Palo Alto, California)
• Trial ID: NCT04249830 on ClinicalTrials.gov

What this trial studies

This clinical trial aims to enhance the safety and effectiveness of stem cell transplants from partially matched donors in children and young adults with hematologic diseases. It utilizes the CliniMACS® TCRαβ-Biotin System and CliniMACS® CD19 to deplete specific T cells and B cells from donor grafts, potentially reducing complications associated with transplants. The trial will assess the efficacy of these modified grafts in treating various malignant and non-malignant disorders when matched donors are unavailable.

Who should consider this trial

Good fit: Ideal candidates include children and young adults under 60 years with life-threatening hematological malignancies or non-malignant disorders who are eligible for allogeneic stem cell transplantation.

Not a fit: Patients with conditions that do not require stem cell transplantation or those over 60 years old may not benefit from this study.

Why it matters

Potential benefit: If successful, this approach could provide a safer and more effective treatment option for young patients with life-threatening hematologic conditions.

How similar studies have performed: Other studies using similar approaches to modify donor cells for transplantation have shown promising results, indicating potential for success in this trial.

Eligibility criteria

Inclusion Criteria for Cohort M and Cohort NM:

1. Age \< 60 years and \> 1 month;
2. Life expectancy \> 10 weeks;
3. Patients deemed eligible for allogeneic HSCT per institutional guidelines;
4. Patients with life-threatening hematological malignancies and non-malignant disorders that could benefit from HSCT;

   a. For malignant patients: i. High-risk acute lymphoblastic leukemia (ALL) in 1st complete remission (CR), ALL in 2nd CR; or ii. High-risk acute myeloid leukemia (AML) in 1st CR, AML in 2nd CR; or iii. Childhood Myelodysplastic Syndrome (MDS) with low blasts (cMDS-LB) or Childhood MDS with increased blasts (cMDS-IB); or iv. Juvenile myelomonocytic leukemia (JMML); or v. Mixed-phenotype acute leukemia (MPAL); or vi. Non-Hodgkin lymphomas in 2nd CR; or vii. Other hematologic malignancies in 1st or 2nd CR eligible for stem cell transplantation per institutional standard b. Patients with non-malignant disorders receiving first HSCT: i. using mis-matched donors, due to the absence of suitable HLA identical sibling or HLA phenotypically identical relative; or ii. whose disease put them at increased risk of graft rejection or GvHD (e.g., Fanconi Anemia, STAT1 gain of function) and therefore can benefit from receiving alpha beta depleted HSCT using as a donor either an HLA identical sibling or an HLA phenotypically identical (10/10 matched) donor;
5. A minimum genotypic identical match of 5/10 is required;
6. The donor and recipient must be identical, as determined by high resolution typing, in at least one allele of each of the following genetic loci: HLA-A, HLA-B, HLA-C, HLA-DQB1 and HLA-DRB1;
7. Lansky/Karnofsky score \> 50; the Karnofsky Scale will be used in subjects ≥ 16 years of age, and the Lansky Scale will be used for those \< 16 years of age.
8. All subjects ≥ 18 years of age must be able to give informed consent or adults lacking capacity to consent must have a legally authorized representative (LAR) available to provide consent. For subjects \<18 years old their legal authorized representative (LAR) (i.e. parent or guardian) must give informed consent. Pediatric subjects will be included in age appropriate discussion and written assent will be obtained for those \> 7 years of age, when appropriate
9. Male and female subjects of childbearing potential must agree to use an effective means of birth control to avoid pregnancy throughout the transplant procedure, while on immunosuppression, and if the subject experiences any chronic GvHD.

Exclusion Criteria for Cohort M and Cohort NM:

1. Pregnant or lactating females;
2. Has received a prior allogenic HSCT;
3. Secondary MDS or AML or treatment related MDS or AML;
4. Dysfunction of liver (ALT/AST \> 10 times upper normal value, or direct bilirubin \> 3 times upper normal value),
5. Serum creatinine \> 1.5 times ULN (for patients not on dialysis) or unmanageable dysfunction of renal function while undergoing dialysis (for patients on dialysis);
6. Severe cardiovascular disease (congestive heart failure or left ventricular ejection fraction \< 30%);
7. Current active infectious disease (including positive HIV serology or viral RNA);
8. Serious concurrent uncontrolled medical disorders;
9. Lack of patient's/parents'/guardian's informed consent;
10. Any severe concurrent disease which, in the judgement of the PI, would place the patient at increased risk during participation in the study.

Where this trial is running

Palo Alto, California

• Lucile Packard Children's Hospital — Palo Alto, California, United States (Recruiting)

Study contacts

• Principal investigator: David Shyr, MD — Clinical Associate Professor, Pediatrics, Stem Cell Transplantation

Conditions Hematologic Diseases